Resource Summary Report

Generated by RRID on Aug 17, 2026

pcDNA3.3-SARS2-B.1.617.2

RRID:Addgene_172320
Type: Plasmid

Proper Citation

RRID:Addgene_172320

Plasmid Information

URL: http://www.addgene.org/172320

Proper Citation: RRID:Addgene_172320

Insert Name: Spike of B.1.617.2 strain

Organism: SARS-CoV-2

Bacterial Resistance: Ampicillin

Defining Citation: PMID:34519517

Vector Backbone Description: Backbone Size:5500; Vector Backbone:pcDNA3.3; Vector Types:Mammalian Expression; Bacterial Resistance:Ampicillin

Plasmid Name: pcDNA3.3-SARS2-B.1.617.2

Relevant Mutation: T19R, 156G, 157-158del, L452R, T478K, D614G, P681R, D950N, c-terminal 18aa deletion

Record Creation Time: 20220422T222000+0000

Record Last Update: 20260815T081023+0000

Ratings and Alerts

No rating or validation information has been found for pcDNA3.3-SARS2-B.1.617.2.

No alerts have been found for pcDNA3.3-SARS2-B.1.617.2.

Data and Source Information

Source: Addgene

Usage and Citation Metrics

We found 37 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Finicle BT, et al. (2026) Endolysosomal trafficking regulator SH-BC-893 inhibits coronavirus entry in vitro and in vivo. Scientific reports, 16(1).

Sulea T, et al. (2026) Multifunctional ACE2-nanobody fusion design for pan-specific neutralization and cardiovascular protection in SARS coronavirus infection. Antimicrobial agents and chemotherapy, 70(5), e0002426.

Dislers A, et al. (2026) Immunogenicity of SARS-CoV-2 vaccine prototype based on virus-like particles of hepatitis B core antigen from genotype G and interleukin 12 expressing Semliki Forest virus as a genetic adjuvant. The Journal of general virology, 107(3).

Chai T, et al. (2026) Elucidating genes sufficient for viral entry into cells through sequential genome-wide CRISPR activation screens. bioRxiv : the preprint server for biology.

Ramasamy S, et al. (2025) Serological Assays Reveal No Evidence of Natural SARS-CoV-2 Infection in US Cattle. Microorganisms, 13(3).

Hwang J, et al. (2025) Fc-binding nanodisc restores antiviral efficacy of antibodies with reduced neutralizing effects against evolving SARS-CoV-2 variants. Journal of nanobiotechnology, 23(1), 44.

Lu J, et al. (2025) Identifying Exifone as a Dual-Target Agent Targeting Both SARS-CoV-2 3CL Protease and the ACE2/S-RBD Interaction Among Clinical Polyphenolic Compounds. International journal of molecular sciences, 26(5).

Hwang J, et al. (2025) Broad-Spectrum Antiviral Styrene Maleic-Acid Copolymer Lipid Particle Nanodiscs for pH-Responsive Irreversible Virus Inactivation. Biomacromolecules, 26(7), 4051.

Va?ová V, et al. (2025) Long-Term Dynamics of SARS-CoV-2 Variant-Specific Neutralizing Antibodies Following mRNA Vaccination and Infection. Viruses, 17(5).

Zúñiga R, et al. (2025) Bromhexine inhibits SARS-CoV-2 Omicron and variant pseudovirus infection via ACE2-targeted mechanisms. Frontiers in pharmacology, 16, 1745277.

Jung I, et al. (2025) Rapid Discovery of Potent Neutralizing Antibodies against SARS-CoV-2 through Directed Evolution of SARS-CoV-1 Antibodies. Molecular pharmaceutics, 22(9), 5316.

Jana ID, et al. (2025) Early 2022 breakthrough infection sera from India target the conserved cryptic class 5 epitope to counteract immune escape by SARS-CoV-2 variants. Journal of virology, 99(4), e0005125.

Shukla N, et al. (2024) Pseudotyped virus infection of multiplexed ACE2 libraries reveals SARS-CoV-2 variant shifts in receptor usage. PLoS pathogens, 20(5), e1012044.

Thümmler L, et al. (2024) Fluoxetine and Sertraline Potently Neutralize the Replication of Distinct SARS-CoV-2 Variants. Viruses, 16(4).

Connor RI, et al. (2024) Characteristics and Functions of Infection-enhancing Antibodies to the N-terminal Domain of SARS-CoV-2. Pathogens & immunity, 9(2), 1.

Manu AA, et al. (2024) Development and utility of a SARS-CoV-2 pseudovirus assay for compound screening and antibody neutralization assays. Heliyon, 10(10), e31392.

Eden T, et al. (2024) Generation of nanobodies from transgenic 'LamaMice' lacking an endogenous immunoglobulin repertoire. Nature communications, 15(1), 4728.

Chawansuntati K, et al. (2024) Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand. Vaccine: X, 18, 100475.

Shukla N, et al. (2024) Pseudotyped virus infection of multiplexed ACE2 libraries reveals SARS-CoV-2 variant shifts in receptor usage. bioRxiv : the preprint server for biology.

Xiang Y, et al. (2023) Ginkgolic acids inhibit SARS-CoV-2 and its variants by blocking the spike protein/ACE2 interplay. International journal of biological macromolecules, 226, 780.